Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience
被引:38
作者:
Mohamed, K
论文数: 0引用数: 0
h-index: 0
机构:
Alder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, EnglandAlder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, England
Mohamed, K
[1
]
Appleton, R
论文数: 0引用数: 0
h-index: 0
机构:
Alder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, EnglandAlder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, England
Appleton, R
[1
]
Rosenbloom, L
论文数: 0引用数: 0
h-index: 0
机构:
Alder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, EnglandAlder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, England
Rosenbloom, L
[1
]
机构:
[1] Alder Hey Childrens Hosp, Dept Neurol, Liverpool L12 2AP, Merseyside, England
来源:
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
|
2000年
/
9卷
/
02期
关键词:
topiramate;
children;
adolescents;
open study;
D O I:
10.1053/seiz.2000.0387
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
A 3-year retrospective review was undertaken of the use of topiramate in 51 children aged 3-16 years with partial and generalized epilepsies who attended a tertiary referral epilepsy centre in a large children's hospital. The mean follow-up period was 19 months (range 6-33 months). Twenty-six children (51%) were still receiving topiramate at the time of their last review. Fifteen children (29%) showed a greater than 50% reduction in their seizure frequency and four children (8%) became seizure free, three on topiramate monotherapy. The drug appeared to be most effective in children with moderate learning difficulties with 75% showing an improvement in seizure control compared with 25% of children with normal educational functioning. Topiramate was withdrawn in 25 patients. The reasons for withdrawal included adverse effects in 20, lack of effect in three and worsening of seizures in two patients. Adverse side effects were reported in 57% of the 51 patients. The majority of the side effects were related to behavioural and cognitive difficulties, with less-common side effects including anorexia, weight loss and headaches. (C) 2000 BEA Trading Ltd.